Post marketing real-world experience of ravulizumab in NMOSD
Early post-marketing real-world experience with ravulizumab in the UAE is consistent with pivotal trial results and aligns with the safety and efficacy profiles reported for other complement-targeted therapies; however, findings are limited by the small sample size and short follow-up.
Authors
- Victoria Mifsud (ORCID: https://orcid.org/0000-0003-4561-1449)
- Luai Eldweik (ORCID: https://orcid.org/0000-0002-6504-646X)
- Ahmed Shatila (ORCID: https://orcid.org/0009-0003-6640-899X)
- Suzi Elhabet
- Gina Lee (ORCID: https://orcid.org/0000-0002-3148-1586)
- Béatrice Benedetti (ORCID: https://orcid.org/0000-0002-5846-0507)
- Anu Jacob
- A. Ben Mahmoud (ORCID: https://orcid.org/0000-0002-1637-4336)
- Rami R Saab
- Ali A Deif
Institutions
- Cleveland Clinic (US)
- Khalifa University of Science and Technology (AE)
- Sheikh Shakhbout Medical City (AE)
- Cleveland Eye Clinic (US)
- The Neurological Institute (US)
Publication Details
- Journal
- Multiple Sclerosis and Related Disorders
- Published
- 2025-09-12
- DOI
- https://doi.org/10.1016/j.msard.2025.106747
- Citations
- 2
- Primary Topic
- Immunodeficiency and Autoimmune Disorders
- Type
- article
- Field-Weighted Citation Impact
- 1.59